SKShun Kaneko

Shun Kaneko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shun Kaneko has a total of 162 co-authors. Here are the top co-authors by number of shared publications:

  • Masayuki Kurosaki

    Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan

    16 shared publications
  • Chiaki Maeyashiki

    Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan

    15 shared publications
  • Namiki Izumi

    Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Musashino 180-8610, Japan

    15 shared publications
  • Mayu Higuchi

    Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan

    14 shared publications
  • Yuka Hayakawa

    Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan

    14 shared publications
  • Hiroyuki Nakanishi

    Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan

    13 shared publications

Latest Publications

  • Open Access

    Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real‐World Clinical Study

    by Shun Kaneko, Yasuhiro Asahina, Miyako Murakawa, Shunsuke Ueyama, Hideki Watanabe, Chiaki Maeyashiki, Akiko Kusano‐Kitazume, Ayako Sato, Kozue Uchidate, Taro Watabe, et al.

    Background/Aim: The global aging population includes an increasing number of elderly patients with hepatocellular carcinoma (HCC). This study aimed to clarify the real‐world outcomes, prognostic factors, and appropriate administration indicators for immunotherapy in elderly HCC patients. Methods: This retrospective multicenter study analyzed 286 patients with unresectable HCC who received first‐line immunotherapy (atezolizumab–bevacizumab or durvalumab‐tremelimumab) between November 2020 and January 2024. Patients were categorized into the late elderly (LE; ≥ 75 years, n = 117) and non‐late elderly (non‐LE; ≤ 74 years, n = 169) groups. Baseline characteristics, overall survival (OS), progression‐free survival (PFS), and prognostic factors were evaluated. Results: The LE group had significantly poorer performance status, lower albumin–bilirubin (ALBI) scores, lower alpha‐fetoprotein (AFP) and alanine transaminase levels, higher creatinine levels, and were significantly less likely to receive post‐immune checkpoint inhibitor (ICI) treatment compared with the non‐LE group (56.2% vs. 38.4%, p = 0.0038). Median OS and PFS for the LE group were 25.6 and 10.5 months, respectively. The LE group demonstrated a comparable disease control rate (82.0%) and safety profile. The ALBI score was a significant prognostic factor for both groups. Post‐ICI treatment significantly improved OS only in the non‐LE group, even after propensity score matching for ALBI score and AFP levels. Conclusions: Immunotherapy is effective and well‐tolerated in LE patients with unresectable HCC, particularly in those with preserved liver function (mALBI grade 1/2a). Post‐ICI treatment significantly benefits non‐LE patients, with limited impact on LE patients, highlighting the need for therapeutic strategies based on age and liver function.


  • Open Access

    Immune-related adverse events in patients with low baseline serum IL-6 treated with durvalumab plus tremelimumab for hepatocellular carcinoma: a case series

    by Tsubasa Nobusawa, Shun Kaneko, Miyako Murakawa, Jun Tsuchiya, Masato Miyoshi, Fukiko Kawai-Kitahata, Mina Nakagawa, Sei Kakinuma, Yasuhiro Asahina, Ryuichi Okamoto

    Systemic therapy for advanced hepatocellular carcinoma (HCC) has progressed significantly, yet the management of immune-related adverse events (irAEs) remains a challenge, particularly with anti-CTLA-4 and anti-PD-L1 antibodies. We present two cases of severe irAEs during durvalumab plus tremelimumab (DT) therapy, demonstrating successful management and favorable outcomes. In Case 1, a 76-year-old male with metabolic-associated steatotic liver disease-related HCC experienced disease progression after lenvatinib and subsequently initiated DT therapy. He developed Grade 3 immune-related myositis at week 5, which was successfully managed with prednisolone. A partial response (PR) was achieved and maintained, with a 55% tumor reduction at 8 months. In Case 2, a 73-year-old male with alcoholic cirrhosis and a 16-cm HCC received DT therapy. On day 19, he developed Grade 3 immune-related hepatitis and thyroiditis, which were controlled with prednisolone. After steroid tapering, durvalumab was successfully rechallenged, maintaining a 38% tumor reduction at 6 months with a sustained PR. In the case series, lower baseline serum interleukin (IL)-6 levels were associated with the development of Grade ≥ 3 irAEs. These findings suggest that IL-6 may serve as a predictive biomarker, aiding in risk assessment and the optimization of individualized treatment strategies prior to anti-CTLA-4 therapy.


  • Open Access

    Genetic alterations in hepatocellular carcinoma after sustained virological response in relation to the molecular characterization of metabolic diseases

    by Fukiko Kawai‐Kitahata, Yasuhiro Asahina, Sei Kakinuma, Kento Inada, Tomohiro Mochida, Keiya Watakabe, Tsubasa Nobusawa, Taro Shimizu, Jun Tsuchiya, Masato Miyoshi, et al.

    Aim: The mechanism of hepatocarcinogenesis after sustained virological response (SVR) in hepatitis C virus (HCV) patients is unclear. We compared gene profiles of hepatocellular carcinoma (HCC) between HCV‐SVR, steatotic liver disease (SLD), and HCV‐non‐SVR patients.Methods: This study analyzed 126 resected HCCs from patients with HCV and SLD, classifying them as HCV‐SVR (n = 22), HCV‐non‐SVR (n = 56), and SLD (n = 48). Deep sequencing of 2910 hotspots in 55 cancer‐related genes was conducted to examine mutations and copy number variations in both cancerous and background liver tissues.Results: The HCV‐SVR group comprised more patients who consumed alcohol (45.5% vs. 15.7%, p = 0.008), were obese (54.5% vs. 17.9%, p = 0.002), and had dyslipidemia (18.2% vs. 3.6%, p = 0.029) and hyperuricemia (18.2% vs. 3.6%, p = 0.029) than the HCV‐non‐SVR group. Mutational profiling of the HCV‐SVR HCC showed significantly lower alteration rates of AXIN1 (13.6% vs. 42.9%, p = 0.016), ARID2 (9.1% vs. 39.3%, p = 0.013), and TP53 (9.1% vs. 32.1%, p = 0.030) than HCV‐non‐SVR patients. Compared with HCV‐non‐SVR‐HCC, SLD‐HCCs showed significantly lower rates of TERT promoter mutations (62.5% vs. 85.7%, p = 0.004), ARID2 alterations (12.5% vs. 39.3%, p = 0.003), and AXIN1 alterations (12.5% vs. 42.9%, p = 0.002). HCV‐SVR/MASH/MASLD/ALD‐HCC had significantly lower alteration rates of the Wnt/β‐catenin (41.4% vs. 60.7%, p = 0.048) and chromatin remodeling pathways (27.1% vs. 48.2%, p = 0.026) than HCV‐non‐SVR‐HCC.Conclusions: HCV‐SVR HCC is linked to alcohol use and metabolic diseases, showing a mutational profile similar to SLD‐HCC.


  • Granulomatous hepatitis with Crohn’s disease: a case report

    by Tatsuya Suzuki, Yuka Hayakawa, Shun Kaneko, Kento Takenaka, Keiya Watakabe, Yuko Kinowaki, Akira Takemoto, Kazuo Ohtsuka, Yasuhiro Asahina, Ryuichi Okamoto

    A 45-year-old man who was regularly followed up for Crohn’s disease (CD) and maintained clinical remission with vedolizumab (VDZ). At 37 years old, he was diagnosed CD from longitudinal ulcers in the distal ileum by balloon-assisted enteroscopy (BAE). During the follow-up, liver enzyme elevation, splenomegaly and thrombocytopenia were in progress. Esophagogastric varices suggested chronic liver disease and portal hypertension. Magnetic resonance elastography (MRE) showed liver stiffness of 3.4 kPa and proton density fat fraction (PDFF) of 1.86%. He was diagnosed with granulomatous hepatitis based on a liver biopsy. The hepatic venous pressure gradient (HVPG) was mildly elevated at 7 mmHg, consistent with the pre-sinusoidal portal hypertension due to granulomatous hepatitis. We report a rare case with granulomatous hepatitis diagnosed from liver injury and portal hypertension, despite the stable intestinal symptoms of CD.


  • Open Access

    Analysis of prognosis and background liver disease in non-advanced hepatocellular carcinoma in two decades

    by Shun Kaneko, Yasuhiro Asahina, Miyako Murakawa, Seishin Azuma, Kento Inada, Tomohiro Mochida, Keiya Watakabe, Taro Shimizu, Jun Tsuchiya, Masato Miyoshi, et al.

    Background/Aim: Antiviral hepatitis and systemic therapies for hepatocellular carcinoma (HCC) remarkably progressed in the recent 10 years. This study aimed to reveal the actual transition and changes in the prognosis and background liver disease in non-advanced HCC in the past 20 years. Methods: This retrospectively recruited 566 patients who were diagnosed with non-advanced HCC from February 2002 to February 2022. The prognosis was analyzed by subdividing according to the diagnosis date (period I: February 2002–April 2009 and period Ⅱ: May 2009–February 2022). Results: Patients in period II (n = 351) were significantly older, with lower albumin-bilirubin (ALBI) scores and alpha-fetoprotein (AFP) and more anti-viral therapy, systemic therapy, and hepatic arterial infusion chemotherapy as compared with those in period I (n = 215). The etiology ratio of the background liver disease revealed decreased hepatitis C virus from 70.6% to 49.0% and increased non-B, non-C from 17.7% to 39.9% from periods I to Ⅱ. The multivariate analysis revealed older age and higher ALBI score in Barcelona Clinic Liver Cancer (BCLC) 0/A stage, AFP of >20 ng/mL, and higher ALBI score in BCLC B stage as independent prognosis factors. Fine-Gray competing risk model analysis revealed that liver-related deaths significantly decreased in period II as compared to period I, especially for BCLC stage 0/A (HR: 0.656; 95%CI: 0.442–0.972, P = 0.036). Conclusion: The characteristics of patients with non-advanced HCC have changed over time. Appropriate background liver management led to better liver-related prognoses in BCLC 0/A.


  • Prognostic significance of C‐reactive protein in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

    by Shun Kaneko, Yasuhiro Asahina, Miyako Murakawa, Shunsuke Ueyama, Chiaki Maeyashiki, Hideki Watanabe, Akiko Kusano‐Kitazume, Ayako Sato, Kozue Uchidate, Takehito Asakawa, et al.

    Aim: C‐reactive protein (CRP) is both an inflammatory and prognostic marker in various cancers. This study aimed to elucidate the characteristics of CRP and the prognostic factors in patients who were administered with atezolizumab plus bevacizumab (ATZ + BEV) for unresectable hepatocellular carcinoma (HCC).Methods: A total of 213 patients who received ATZ + BEV for HCC from November 2020 to March 2023 at 15 hospitals were enrolled in this retrospective study. The prognosis was analyzed by subdividing the patients based on baseline characteristics, radiologic response, and treatment lines. Accuracy of survival prediction was assessed using CRP, alpha fetoprotein (AFP), C‐reactive protein and alpha fetoprotein in immunotherapy (CRAFITY), and Glasgow Prognostic Score.Results: Compared with patients with baseline CRP n = 45) had a significantly higher baseline albumin–bilirubin score and AFP levels, significantly lower disease control rate (62.2%), and significantly shorter median overall survival (hazards ratios 2.292; 95% confidence interval 1.313–5.107; log‐rank test, p < 0.001). Multivariate analysis identified CRP ≥1 mg/dL, AFP ≥100 ng/mL, and modified albumin–bilirubin grade as the significant prognostic factors. The baseline CRP, AFP, CRAFITY, and Glasgow Prognostic Score demonstrated higher discrimination for 1‐year survival prediction after first‐line ATZ + BEV administration, compared with beyond second line, with area under the receiver operating characteristic curves of 0.759, 0.761, 0.805, and 0.717, respectively.Conclusions: CRP was a significant biomarker in patients treated with ATZ + BEV for HCC. Elevated CRP levels may indicate aggressive cancer progression and potential resistance to ATZ + BEV therapy.


  • Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors

    by Shun Kaneko, Yasuhiro Asahina, Mina Nakagawa, Miyako Murakawa, Yasunari Miyazaki, Takahiro Asakage, Shohei Fukuda, Takeshi Namiki, Yoshihito Kano, Masashi Nagata, et al.

    Aim: The use of immune checkpoint inhibitors (ICIs) has increased remarkably, and immune‐related adverse events (irAEs) have also increased. This study aimed to identify factors associated with immune‐related liver injury (irLI), and the relationship between the grades of irLI and overall survival (OS) in patients treated with ICIs.Methods: A total of 571 patients who had been treated for advanced malignancies with ICIs between January 2015 and March 2022 were retrospectively recruited. The presence of liver injury was determined by the aspartate aminotransferase and alanine aminotransferase elevation. The irLI grading was based on Common Terminology Criteria for Adverse Events version 5.0.Results: A total of 50 (8.8%) patients had grade ≥2 irLI and 24 (4.2%) had grade ≥3 irLI. Treatment with anti‐cytotoxic T‐lymphocyte‐associated protein‐4 agents and baseline grade 1 aspartate aminotransferase/alanine aminotransferase elevation were independent predictive factors of grade ≥2 irLI. Treatment with anti‐cytotoxic T‐lymphocyte‐associated protein‐4 was the only independent predictive factor of grade ≥3 irLI. The median OS for patients who experienced any irAEs was significantly longer than of those without irAEs (hazard ratio 0.503, 95% CI 0.398–0.636, p < 0.001). The median OS in patients with grade ≥2 irLI was significantly longer (HR 0.570, 95% CI 0.387–0.838, p = 0.022). There was no significant difference between the median OS in patients with grade ≥3 irLI and the others (p = 0.11).Conclusion: The incidence of irLI was significantly higher in patients treated with anti‐cytotoxic T‐lymphocyte‐associated protein‐4 agents. Even in patients with pre‐existing grade 1 aspartate aminotransferase/alanine aminotransferase elevation, appropriate follow‐up and control of the irLI can improve the prognosis.


  • Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B

    by Shun Kaneko, Masayuki Kurosaki, Toshie Mashiba, Hiroyuki Marusawa, Masahiko Kondo, Yuji Kojima, Yasushi Uchida, Hideki Fujii, Takehiro Akahane, Hitoshi Yagisawa, et al.

    Nucleos(t)ide analogs (NAs) cannot completely suppress the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed to identify the risk factors for HCC development in naïve CHB patients treated with current NA. Patients receiving NA ( n = 905) were recruited retrospectively from the 17 hospitals of the Japanese Red Cross Liver Study Group. All treatment‐naïve patients had been receiving current NA continuously for more than 1 year until the end of the follow‐up. We analyzed the accuracy of predictive risk score using the area under receiver operating characteristic curve. The albumin–bilirubin (ALBI) score was significantly improved by NA therapy (−0.171 ± 0.396; p < 0.001 at Week 48). A total of 72 (8.0%) patients developed HCC over a median follow‐up of 6.2 (1.03–15.7) years. An independent predictive factor of HCC development was older age, cirrhosis, lower platelet counts at baseline and ALBI score, and alpha‐fetoprotein (AFP) at 1 year after NA therapy according to multivariate analysis. The accuracy was assessed using the PAGE‐B, mPAGE‐B, aMAP, APA‐B, and REAL‐B scores that included these factors. Discrimination was generally acceptable for these models. aMAP and REAL‐B demonstrated high discrimination with 0.866/0.862 and 0.833/0.859 for 3‐ and 5‐year prediction from the status of 1 year after NA therapy, respectively. Baseline age and platelet count, as well as ALBI and AFP one year after NA, were useful for stratifying carcinogenesis risk. The aMAP and REAL‐B scores were validated with high accuracy in Japanese CHB patients.


  • Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B

    by Sakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, Shun Kaneko, Kento Inada, Yuki Tanaka, Shun Ishido, Koji Yamashita, Tsubasa Nobusawa, Hiroaki Matsumoto, et al.

    Aim: Alanine aminotransferase (ALT) is a criterion for the introduction of nucleotide/nucleoside analog (NA), and ALT levels are decreased by NA treatment. However, the association between post‐treatment ALT levels and hepatocellular carcinoma (HCC) risk remains unclear. To fill this gap, we aimed to establish a target value of ALT level during NA treatment.Methods: In total, 413 patients with chronic hepatitis B who received entecavir, tenofovir alafenamide, or tenofovir disoproxil fumarate were enrolled. The subsequent development of HCC was examined and a target value of ALT level during NA treatment as a risk marker for HCC was evaluated.Results: The median follow‐up duration was 5.1 years, during which time 27 patients (8.6%) developed HCC. ALT level at the start of treatment was not associated with HCC development (p = 0.08). When stratified by ALT at 1 year after NA initiation, the cumulative 3‐ and 5‐year rates of HCC for patients with ALT ≥21 IU/L were 11.5% and 18.1%, and those with ALT p = 0.002). In multivariable analysis adjusting age, sex, and platelet counts, ALT ≥21 IU/L was an independent risk factor of HCC development with hazard ratio of 4.5 (95% confidence interval: 1.01–20.4).Conclusions: ALT <21 IU/L at 1 year after NA initiation has a lower risk of HCC and could be used as a target value for NA treatment.